Summary

Overview
Global Hysteroscopy Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Hysteroscopy is primarily used to identify and treat conditions that cause abnormal uterine bleeding, heavy menstrual bleeding, irregular spotting between periods, and bleeding after menopause. The procedure allows the surgeon to look inside of uterus with a tool called a hysteroscope. It is typically performed in a hospital or outpatient surgical center and is usually done under general or spinal anesthesia.
Hysteroscopy can be a part of the diagnostic process, as well as the treatment process. Diagnostic hysteroscopy identifies structural irregularities in the uterus and also can be used to confirm the results of other tests such as an ultrasound. Operative hysteroscopy treats an abnormality detected during a diagnostic hysteroscopy and endometrial ablation is a common procedure that treats abnormal uterine bleeding.
Furthermore, significant growth drivers such as increasing technological advancements, product launches, and rising investments give rise to future market growth. Significant key players like Medtronic Plc., Olympus Corporation, B. Braun Melsungen AG, Stryker Corporation, Hologic Inc., and others are actively operating in the market.
Dynamics
Increasing Product Launches for Hysteroscopy Devices
Hysteroscopy is done using a hysteroscope which is a thin, lighted tube that is inserted into the vagina to examine the cervix and inside of the uterus. The product launches by major companies help to drive market growth and these effective research and developments help in product launches for new diagnoses, and treatments to improve care for millions of people with gynecological diseases.
For instance, in July 2023, GenWorks Health launched a mechanical hysteroscopic tissue removal system that uses a simple mechanical approach for removing intrauterine tissues. It is a minimally invasive system that has been demonstrated to be quicker and can also completely remove endometrial fibroids and polyps.
Additionally, in June 2022, UroViu Corporation launched the new Hystero-V, a single-use hysteroscope compatible with UroViu's Always Ready endoscopy platform. The 12-Fr, semi-rigid, Hystero-V features a hydrophilic coating enabling gentle insertion and superior visualization for highly effective intrauterine examinations. Hence, due to the above factors, the market is expected to boost over the forecast period.
Rising Investments in Hysteroscopy
Hysteroscopy is a minimally invasive intervention that can be used to diagnose and treat many intrauterine and endocervical problems. The major investments from key companies help to drive market growth and these effective funds from national organizations and companies help to transform research discoveries into new diagnoses and treatments for gynecology diseases.
For instance, in October 2020, Meditrina raised $13 million to commercialize the Aveta system for treating intrauterine pathologies. The Aveta system is designed to use a proprietary expandable working channel hysteroscope, along with a fluid management and resection system, for hysteroscopic tissue chip resection under continuous flow conditions
Drawbacks Associated with Hysteroscopy will Hamper the Market Growth
Drawbacks associated with hysteroscopy include the high cost of hysteroscopy devices and procedures, lack of trained professionals in developing countries, risk of complications and infections associated with the procedure, lack of awareness and reluctance towards minimally invasive procedures in some regions, stringent regulations for approval of hysteroscopy devices and limited access to advanced healthcare facilities in rural areas. For instance, in the United States, the total cost of hysteroscopy varies between $2800 and $4800. Hence, these factors are limiting the market growth.
Segment Analysis
The global hysteroscopy market is segmented based on product, application, end users, and region.
Tissue Removal Hysteroscopy Systems from the Product Type Segment Accounted for Approximately XX% of the Global Hysteroscopy Market
The use of mechanical tissue removal hysteroscopy systems is more frequently implemented as the first-line approach for the treatment of intrauterine pathology. Hysteroscopic tissue removal and retrieval is a procedure performed under local or general anesthesia that allows the doctor to check inside the uterus and remove any polyps or fibroids under direct vision. Tissue removal hysteroscopy systems are expected to hold the largest market share over the period forecast owing to increasing product launches and technical advancements.
For instance, in November 2022, Medtronic plc, launched the TruClear system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intrauterine abnormalities (IUA). TruClear is a next-generation device that provides practitioners with a clear operative field and patients with gentle mechanical resection during the procedure to help efficiently execute a hysteroscopy.
Additionally, in February 2021, VirtaMed launched a hysteroscopy and gynecological laparoscopy mixed tissue removal platform. VirtaMed’s hysteroscopy system has been updated to include 16 cases for MyoSure tissue removal, added to over 50 cases in diagnostics, polypectomy, myomectomy, and tissue ablation. Hence, the above factors help to accelerate the market growth.
Geographical Penetration
North America Accounted for Approximately 38.4% of the Market Share in 2022
The global hysteroscopy market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant proportion of the hysteroscopy market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising prevalence and incidence of hysterectomy, and product launches in hysteroscopy devices.
For instance, according to the Centers for Disease Control and Prevention,2022, it states that hysterectomy is the second most common surgical procedure for women and approximately 600,000 hysterectomies are performed in the United States each year. Additionally, From 2012 to 2020, the age-standardized hysterectomy prevalence among adult U.S. women was 17.9%. It steadily increased with each consecutive age group and was highest among women aged more than 80 years (48.8%).
Furthermore, in December 2020, Hologic, Inc. launched its Omni hysteroscope which is an innovative three-in-one modular scope with advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures. The Omni scope, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA) is designed to help physicians streamline the process of diagnosing and treating patients
Competitive Landscape
The major global players in the market include Medtronic Plc., Olympus Corporation, B. Braun Melsungen AG, Stryker Corporation, Hologic Inc., CooperSurgical Inc., XION GmbH, Richard Wolf GmbH, Karl Storz SE & Co., Delmont Imaging among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global hysteroscopy market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device launches, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduces the diagnosis of many patients suffering from various gynecology and obstetrics disorders.
Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the hysteroscopy market is expected to be moderately affected over the forecast period.
By Product
• Fluid Management Hysteroscopy Systems
• Tissue Removal Hysteroscopy Systems
• Hand-held Hysteroscopy Systems
• Hysteroscopes
o Flexible hysteroscopes
o Rigid hysteroscopes
o Contact hysteroscopes
• Hysterosheaths
• Others
By Application
• Tubal Sterilization
• Hysterectomy
• Polypectomy
• Myomectomy
• Endometrial Ablation
• Others
By End Users
• Hospitals
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In October 2022, UroViu Corporation secured a medical equipment ECAT contract for VA DoD Purchasing. The single-use platform ranges from a 12-Fr diagnostic semi-rigid cystoscope and equivalent hysteroscope, a 14-Fr injection cystoscope with an integrated needle for drug delivery, to a flexible, deflectable, and rotatable 16.5-Fr cystoscope.
• In October 2021, Hologic, Inc. launched an expanded Omni suite, a comprehensive gynecological surgical offering. The expanded Omni suite aims to optimize diagnostic and operative hysteroscopy in Europe, Africa, and the Middle East (EMEA). The expanded offering includes the Omni 30° hysteroscope, Omni Lok cervical seal, and Omni 5 French seal.
Why Purchase the Report?
• To visualize the global hysteroscopy market segmentation based on product, application, end users, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global hysteroscopy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hysteroscopy market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents